: At the time of its discovery, it was referred to in lab journals as "Methylsafrylamin" .
: Discussions and production began around this time for film adaptations of related literature, such as Irvine Welsh's Ecstasy . Extasy 09 (2006)
: Research published in August 2006 confirmed that Merck did not initially market the drug for weight loss; it was essentially a chemical byproduct of other research into life-saving medicines. Medical and Scientific Context (2006) : At the time of its discovery, it
: Research published in late 2006 identified patterns of ecstasy-associated hyponatremia (dangerously low sodium levels), often occurring in female users. Medical and Scientific Context (2006) : Research published
: Studies in December 2006 highlighted that frequent high-dose use is associated with brain damage , specifically reduced levels of serotonin transporters.
The year 2006 was a pivotal time for scientific literature regarding the drug's long-term impact on the human body.
: Functional abnormalities noted in users at this time included memory disturbances, impulsivity, and depression.